Advertisement
Advertisement
U.S. markets open in 8 hours 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
20.07+2.57 (+14.69%)
At close: 04:00PM EDT
20.35 +0.28 (+1.40%)
After hours: 07:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close17.50
Open17.50
Bid0.00 x 1200
Ask0.00 x 900
Day's Range16.86 - 20.44
52 Week Range6.54 - 49.51
Volume811,947
Avg. Volume355,174
Market Cap853.425M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.94
Earnings DateAug 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CMPS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • COMPASS Pathways Plc - American
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Motley Fool

    COMPASS Pathways plc (CMPS) Q2 2022 Earnings Call Transcript

    Again, my name is Steve Schultz, senior vice president of investor relations at COMPASS Pathways. The call is being recorded and will be available on the COMPASS Pathways' Investor Relations website shortly after the conclusion of the call.

  • GlobeNewswire

    COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

    LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under reviewCOMP360 phase II study in anorexia nervosa launchedCash position at 30 June 2022 of $207.2 millionConference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results

  • GlobeNewswire

    COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

    LONDON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that COMPASS granted a non-qualified share option to purchase an aggregate of 600,000 ordinary shares, nominal value £0.008 each, in the capital of the Company to Kabir Nath, COMPASS’s newly appointed chief executive officer. In accordance with NASDAQ Listing Rule 5635(c)(4),

Advertisement
Advertisement